BioCentra

Executive Summary

BioCentra is a US-based diagnostics company leveraging its proprietary TBioScan® technology to address critical unmet needs in neurological and cardiovascular testing. The company's primary focus is on providing advanced diagnostic tools for mild traumatic brain injury (TBI), a condition often underdiagnosed due to the limitations of current assessment methods. Additionally, BioCentra offers screening tests for dementia/Alzheimer's disease and cardiovascular conditions, positioning itself in growing markets driven by aging populations and increased awareness of brain health. With over two decades since its founding in 2003, the company has established a presence in Cranbury, New Jersey, yet remains private and early-stage in commercialization. Its platform aims to deliver accurate, reliable, and timely results to neurologists and other clinicians, potentially improving patient outcomes and reducing healthcare costs. However, the company faces significant competition from established diagnostics firms and must navigate regulatory pathways to bring its tests to market. The success of BioCentra hinges on clinical validation, adoption by key opinion leaders, and strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for TBioScan TBI test60% success
• Q2 2027Publication of pivotal clinical trial data for Alzheimer's screening50% success
• Q3 2026Strategic partnership with major hospital network40% success